Generics in the United States
MarketLine, January 2013, Pages: 34
Introduction
Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United States generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices. Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume. All currency conversions were calculated at constant average annual 2011 exchange rates.
- The US generics market had total revenues of $73,377.4 million in 2011, representing a compound annual growth rate (CAGR) of 6.9% between 2007 and 2011.
- Market consumption volumes increased with a CAGR of 2.9% between 2007 and 2011, to reach 75.4% of total pharma market volume in 2011.
- The performance of the market is forecast to decelerate, with an anticipated CAGR of 4% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $89,439.2 million by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the United States economy
Key Questions Answered
What was the size of the United States generics market by value in 2011?
What will be the size of the United States generics market in 2016?
What factors are affecting the strength of competition in the United States generics market?
How has the market performed over the last five years?
How large is the United States’s generics market in relation to its regional counterparts?
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Sandoz International GmbH 19
Mylan Inc 20
Teva Pharmaceutical Industries 23
Watson Pharmaceuticals Inc 27
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related MarketLine research 33
LIST OF TABLES
Table 1: United States generics market value: $ billion, 2007–11 8
Table 1: United States generics market volume: % of total Pharma volume, 2007–11 9
Table 1: United States generics market geography segmentation: $ billion, 2011 10
Table 1: United States generics market value forecast: $ billion, 2011–16 11
Table 1: United States generics market volume forecast: % of total Pharma volume, 2011–16 12
Table 1: Sandoz International GmbH: key facts 19
Table 1: Mylan Inc: key facts 20
Table 1: Mylan Inc: key financials ($) 21
Table 1: Mylan Inc: key financial ratios 21
Table 1: Teva Pharmaceutical Industries: key facts 23
Table 1: Teva Pharmaceutical Industries: key financials ($) 24
Table 1: Teva Pharmaceutical Industries: key financial ratios 25
Table 1: Watson Pharmaceuticals Inc: key facts 27
Table 1: Watson Pharmaceuticals Inc: key financials ($) 28
Table 1: Watson Pharmaceuticals Inc: key financial ratios 28
Table 1: United States size of population (million), 2007–11 30
Table 1: United States gdp (constant 2000 prices, $ billion), 2007–11 30
Table 1: United States gdp (current prices, $ billion), 2007–11 30
Table 1: United States inflation, 2007–11 31
Table 1: United States consumer price index (absolute), 2007–11 31
Table 1: United States exchange rate, 2007–11 31
LIST OF FIGURES
Figure 1: United States generics market value: $ billion, 2007–11 8
Figure 1: United States generics market volume: % of total Pharma volume, 2007–11 9
Figure 1: United States generics market geography segmentation: % share, by value, 2011 10
Figure 1: United States generics market value forecast: $ billion, 2011–16 11
Figure 1: United States generics market volume forecast: % of total Pharma volume, 2011–16 12
Figure 1: Forces driving competition in the generics market in the United States, 2011 13
Figure 1: Drivers of buyer power in the generics market in the United States, 2011 14
Figure 1: Drivers of supplier power in the generics market in the United States, 2011 15
Figure 1: Factors influencing the likelihood of new entrants in the generics market in the United States, 2011 16
Figure 1: Factors influencing the threat of substitutes in the generics market in the United States, 2011 17
Figure 1: Drivers of degree of rivalry in the generics market in the United States, 2011 18
Figure 1: Mylan Inc: revenues & profitability 21
Figure 1: Mylan Inc: assets & liabilities 22
Figure 1: Teva Pharmaceutical Industries: revenues & profitability 25
Figure 1: Teva Pharmaceutical Industries: assets & liabilities 26
Figure 1: Watson Pharmaceuticals Inc: revenues & profitability 28
Figure 1: Watson Pharmaceuticals Inc: assets & liabilities 29
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
